Advanced

Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism.

Ahmad, Abrar LU ; Sundquist, Kristina LU ; Zöller, Bengt LU ; Svensson, Peter LU ; Sundquist, Jan LU and Memon, Ashfaque LU (2016) In Journal of Thrombosis and Thrombolysis 42(1). p.135-141
Abstract
Thrombomodulin gene (THBD) is a critical cofactor in protein C anticoagulant system. THBD c.1418C>T polymorphism is reported to be associated with higher risk of primary venous thromboembolism (VTE) but its role in VTE recurrence is unknown. The aim of this study was to investigate the role of THBD polymorphism in VTE recurrence. THBD c.1418C>T polymorphism was genotyped by using Taqman polymerase chain reaction in a prospective population based study of 1465 consecutive objectively verified VTE patients. Uni- and multivariate Cox regression were performed for the risk assessment of VTE recurrence. Patients who had VTE before inclusion or had recurrence or died during anticoagulant treatment were excluded. Among the remaining (N =... (More)
Thrombomodulin gene (THBD) is a critical cofactor in protein C anticoagulant system. THBD c.1418C>T polymorphism is reported to be associated with higher risk of primary venous thromboembolism (VTE) but its role in VTE recurrence is unknown. The aim of this study was to investigate the role of THBD polymorphism in VTE recurrence. THBD c.1418C>T polymorphism was genotyped by using Taqman polymerase chain reaction in a prospective population based study of 1465 consecutive objectively verified VTE patients. Uni- and multivariate Cox regression were performed for the risk assessment of VTE recurrence. Patients who had VTE before inclusion or had recurrence or died during anticoagulant treatment were excluded. Among the remaining (N = 1046) patients, 126 (12.05 %) had VTE recurrence during the follow up period (from 1998 to 2008). THBD polymorphism was not significantly associated with risk of VTE recurrence in the univariate [Hazard ratio (HR) 1.11, 95 % confidence interval (CI) 0.78-1.59, p = 0.55] as well as the multivariate analysis adjusted for age, sex and thrombophilia (HR 1.11, 95 % CI 0.78-1.59, p = 0.54). Similarly, in unprovoked first VTE (n = 614), no association was observed between THBD polymorphism and risk of VTE recurrence (HR 1.22 and 95 % CI 0.78-1.89, p = 0.38). In this prospective study, our results do not suggest a predictive role for THBD c.1418C>T polymorphism in VTE recurrence. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Thrombosis and Thrombolysis
volume
42
issue
1
pages
135 - 141
publisher
Springer
external identifiers
  • pmid:26743062
  • scopus:84953396647
  • wos:000376644500018
ISSN
1573-742X
DOI
10.1007/s11239-015-1328-x
language
English
LU publication?
yes
id
2a11cfbb-a17b-46de-b719-3a83ceffb2ee (old id 8592772)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26743062?dopt=Abstract
date added to LUP
2016-02-02 09:09:29
date last changed
2017-05-28 04:37:20
@article{2a11cfbb-a17b-46de-b719-3a83ceffb2ee,
  abstract     = {Thrombomodulin gene (THBD) is a critical cofactor in protein C anticoagulant system. THBD c.1418C>T polymorphism is reported to be associated with higher risk of primary venous thromboembolism (VTE) but its role in VTE recurrence is unknown. The aim of this study was to investigate the role of THBD polymorphism in VTE recurrence. THBD c.1418C>T polymorphism was genotyped by using Taqman polymerase chain reaction in a prospective population based study of 1465 consecutive objectively verified VTE patients. Uni- and multivariate Cox regression were performed for the risk assessment of VTE recurrence. Patients who had VTE before inclusion or had recurrence or died during anticoagulant treatment were excluded. Among the remaining (N = 1046) patients, 126 (12.05 %) had VTE recurrence during the follow up period (from 1998 to 2008). THBD polymorphism was not significantly associated with risk of VTE recurrence in the univariate [Hazard ratio (HR) 1.11, 95 % confidence interval (CI) 0.78-1.59, p = 0.55] as well as the multivariate analysis adjusted for age, sex and thrombophilia (HR 1.11, 95 % CI 0.78-1.59, p = 0.54). Similarly, in unprovoked first VTE (n = 614), no association was observed between THBD polymorphism and risk of VTE recurrence (HR 1.22 and 95 % CI 0.78-1.89, p = 0.38). In this prospective study, our results do not suggest a predictive role for THBD c.1418C>T polymorphism in VTE recurrence.},
  author       = {Ahmad, Abrar and Sundquist, Kristina and Zöller, Bengt and Svensson, Peter and Sundquist, Jan and Memon, Ashfaque},
  issn         = {1573-742X},
  language     = {eng},
  month        = {01},
  number       = {1},
  pages        = {135--141},
  publisher    = {Springer},
  series       = {Journal of Thrombosis and Thrombolysis},
  title        = {Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism.},
  url          = {http://dx.doi.org/10.1007/s11239-015-1328-x},
  volume       = {42},
  year         = {2016},
}